Sanctuary Advisors LLC Lowers Stake in Hologic, Inc. (NASDAQ:HOLX)

Sanctuary Advisors LLC lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,508 shares of the medical equipment provider’s stock after selling 1,105 shares during the period. Sanctuary Advisors LLC’s holdings in Hologic were worth $1,119,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. General Partner Inc. purchased a new stake in Hologic during the fourth quarter valued at about $26,000. First Horizon Advisors Inc. grew its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Covestor Ltd grew its position in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares during the period. Loomis Sayles & Co. L P grew its position in Hologic by 29.3% during the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 183 shares during the period. Finally, Sound Income Strategies LLC purchased a new stake in Hologic during the fourth quarter valued at about $60,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.88% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HOLX. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Stock Down 1.3 %

Shares of NASDAQ:HOLX opened at $64.36 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $69.48 and a 200 day simple moving average of $76.19. The firm has a market cap of $14.44 billion, a PE ratio of 20.30, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.